Divine Aleru, Microbiome Signatures Research Coordinator

This review explores the link between IBD and thromboembolic events, highlighting the increased risks, particularly in patients with active disease, corticosteroid treatment, and post-surgery. It emphasizes the need for thromboprophylaxis and further research on the pathophysiology of these complications.

This study explores the long-term risk of developing IBD in AIH patients, identifying smoking as a significant risk factor and showing that while IBD increases cirrhosis prevalence, it does not worsen liver-related complications in AIH patients.

This review explores the relationship between pyoderma gangrenosum and inflammatory bowel disease, focusing on epidemiology, clinical features, and treatment approaches. It emphasizes the need for more research to standardize diagnosis and treatment protocols, especially in light of the growing use of biologics.

This review discusses the extraintestinal manifestations of IBD, focusing on the pathophysiology, prevalence, and associations with treatment. It emphasizes the role of immune system dysfunction, genetics, and microbiome in triggering these manifestations, with implications for clinical management.

This review explores ocular manifestations in IBD, including episcleritis, uveitis, and scleritis, discussing their pathophysiology, epidemiology, and management, with an emphasis on the role of IBD treatments and the impact of the microbiome.

This review updates the current understanding of PSC-IBD, discussing its unique clinical features, the increased risk of malignancies, and the challenges in managing this comorbidity.

This systematic review and meta-analysis examines the incidence and risk factors for paradoxical psoriasis or psoriasiform lesions in IBD patients treated with anti-TNF therapy, providing crucial insights into the dermatological side effects of these commonly prescribed medications.

This study finds that psoriasis is associated with an increased risk of developing inflammatory bowel disease, particularly ulcerative colitis, emphasizing the importance of early gastrointestinal monitoring in psoriasis patients.

This review examines the genetic, immune, and microbiological links between psoriasis and inflammatory bowel disease, focusing on shared pathophysiological mechanisms and treatment strategies.

This review discusses the pathogenesis of ankylosing spondylitis, highlighting the role of Type 17 immune responses, gut microbiome dysbiosis, and metabolic factors in disease development. It also explores therapeutic advancements targeting these pathways.

This article investigates the relationship between ankylosing spondylitis, Crohn’s disease, Klebsiella pneumoniae, and starch consumption, suggesting that high starch intake may trigger the growth of Klebsiella and exacerbate disease symptoms, with potential therapeutic implications for dietary management.

This study provides a comprehensive meta-analysis on the prevalence and bidirectional association between inflammatory bowel disease (IBD) and autoimmune liver disease (AILD), shedding light on the significant overlap between these conditions and their shared pathophysiological mechanisms.

This review explores the pathophysiology, prevalence, and treatment strategies for extraintestinal manifestations (EIMs) in Crohn’s disease and ulcerative colitis, emphasizing the role of immune responses, microbiome alterations, and biologic therapies in managing these systemic conditions.

This study examines the clinical features, risk factors, and treatment outcomes of intra-abdominal abscesses (IA) and intestinal free-wall perforations (IP) in Korean patients with Crohn’s disease, highlighting the role of intestinal stricture and disease behavior in complication development.

This review explores the pathophysiology, risk factors, and management of intestinal strictures in Crohn’s Disease, emphasizing genetic, environmental, and imaging factors, as well as current therapeutic approaches.

This review explores environmental risk factors for Crohn’s disease and ulcerative colitis, highlighting modifiable exposures such as smoking, diet, and early-life antibiotic use, and their impact on disease prevention.

This review explores the role of epithelial barrier dysfunction and microbial dysbiosis in the pathogenesis of Crohn’s disease, highlighting the impact of genetic, environmental, and microbiota factors on disease progression and the potential for therapeutic strategies to restore barrier integrity and balance microbial communities.

This review focuses on the complex pathogenesis of Crohn’s Disease, exploring the roles of microbiome dysbiosis, immune system dysregulation, and environmental factors in disease progression, while highlighting novel therapeutic and diagnostic strategies

This review explores the evolving role of microbiome-targeted therapies in Crohn’s disease, focusing on microbial dysbiosis and its implications for disease progression and treatment.

The study examines the role of microbiome in IBD, highlighting its potential in diagnosing, predicting disease progression, and personalizing treatments.

This study shows women with PCOS have elevated blood lead and cadmium and reduced magnesium, calcium, and manganese—disrupting hormone levels through oxidative stress and possibly altering gut microbiota.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age, characterized by irregular menstrual cycles, hyperandrogenism, and insulin resistance. It is often associated with metabolic dysfunctions and inflammation, leading to fertility issues and increased risk of type 2 diabetes and cardiovascular disease.

Escherichia coli Nissle 1917 (EcN) is a rare, non-pathogenic strain of E. coli discovered during World War I from a soldier who did not get dysentery while others did. Unlike harmful E. coli, EcN acts as a probiotic: it settles in the gut, competes with bad bacteria for food and space, produces natural antimicrobials, and even helps strengthen the gut barrier.

Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its “silent” progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.